china glp-1 More Chinese biotechs challenge dominance in diabetes China approval for Eli Lilly

This is not about choosing one strategy over another

it is custom to each patient

Recent Updates Eli Lilly's Strategic Expansion: Eli Lilly's $6.5 billion investment in a new manufacturing facility underscores its commitment to scaling production of GLP-1 therapies

Stopping GLP-1 medications can amplify these shifts, as your body adjusts to new hunger and metabolic signals

For once-weekly semaglutide, administer within 5 days of the missed dose

I think it is unlikely we will see such a significant price difference between the pen and the oral tablet as we have seen in other countries, given the pen is very competitively priced in the UK, compared to say the USA for example, says Dr Luke Pratsides, chief medical officer at Get A Drip